1 | Not yet recruiting | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer
|
||||
2 | Active, not recruiting | Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|
||||
3 | Active, not recruiting | AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
|
||||
4 | Active, not recruiting | Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer
|
||||
5 | Active, not recruiting | A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.
|
||||
6 | Active, not recruiting | Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
|
||||
7 | Active, not recruiting | Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
|
||||
8 | Active, not recruiting | A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer
|
||||
9 | Active, not recruiting | SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
|
||||
10 | Recruiting | Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone
|
||||
11 | Active, not recruiting | An Open Label Treatment Extension Study of AMG 706
|
||||
12 | Recruiting | Romiplostim Treatment of Thrombocytopenia in Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
|
Svenska cancerstudier 2010 inom bolaget Amgen
2010/03/29 av georgeschottl
Lämna en kommentar